Venn Life Sciences has bid €6.5m ($7.2m) for preclinical CRO Kinesis Pharma BV in a move prompted by increased Big Pharma focus of efficient early phase drug discovery.
London-listed CRO Venn Life Sciences hopes partnering with academics will help generate drug industry interest in its recently expanded skin model tech business.